



ASX & Media Release

Lead Product PAT-SM6 Shows Promise in Multiple Myeloma

- **Lead Product PAT-SM6 demonstrates activity in preclinical multiple myeloma studies**
- **PAT-SM6 data supports expansion of clinical trial programme into additional key cancer indication**

Melbourne, Australia; 26 September, 2011: Patrys Limited (ASX: PAB; “the Company”), today announced that its lead anti-cancer antibody PAT-SM6 has shown significant activity in preclinical studies of multiple myeloma.

Multiple myeloma is a type of bone marrow cancer arising from plasma cells, and new therapies are desperately needed to treat patients who become resistant to established chemotherapeutics.

The work was performed by Dr Leo Rasche and his associates at the Department of Hematology and Oncology, University Hospital of Würzburg, as part of an ongoing collaboration with Patrys.

Dr Marie Roskrow, Patrys’ CEO said: “This preclinical work is exciting for Patrys because it expands the potential indications for our lead product PAT-SM6, which is already in a clinical trial here in Australia. This data is strong enough for us to consider looking at an additional trial in treatment-resistant multiple myeloma.”

“A trial in patients with this disease is attractive from a development perspective as it is possible to determine very quickly whether the product is working by assessing routine blood counts and bone marrow samples. There is also a substantial population of patients with resistant multiple myeloma, so offering a novel treatment is a significant opportunity for this group to participate in a trial. We will definitely be looking at the possibility of a clinical study based on this proof of concept preclinical work.”

This additional indication adds to a recent expansion of positive in vivo preclinical cancer models for PAT-SM6 which covers a wide range of solid tumours.

PAT-SM6 is a natural human antibody that has shown promise as a potential treatment for multiple types of cancer. It is the first reported clinical product to target an important protein on the surface of cancer cells called GRP78 that plays a number of key roles in cancer cell survival, growth and metastasis.

- Ends -

For further information, please contact:

Patrys Limited:
Dr. Marie Roskrow
Chief Executive Officer
P: +61 3 9670 3273
info@patrys.com

Patrys IR:
Rebecca Wilson
Buchan Consulting
P: 0417 382 391
rwilson@bcg.com.au

Patrys Media:
Tom Donovan
Buchan Consulting
P: +61 3 9866 4722
tdonovan@bcg.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibody therapies for cancer. Patrys has a deep pipeline of internal development candidates and additional products that are the subject of a collaboration agreement with a larger industry partner. More information can be found at www.patrys.com.

About PAT-SM6:

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. More specifically, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type or patient age, gender or disease stage. With respect to melanoma, PAT-SM6 has shown particularly strong promise. In October 2010, Patrys initiated a human clinical trial to evaluate PAT-SM6 as a therapy for melanoma. To date, the second group of patients has been treated and Patrys received approval to progress the clinical trial. Significantly, no safety issues have been observed or reported for any patients treated, to date, with PAT-SM6. Additionally, recent analysis of tumour samples from two patients treated with PAT-SM6 found that the antibody had penetrated into the tumour biopsies, even though the doses were substantially below the anticipated therapeutic levels. The clinical trial is taking place at the Royal Adelaide Hospital Cancer Centre and associated Pain and Anaesthesia Research Clinic and the Princess Alexandra Hospital, Brisbane. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and the mechanism of action.

About Multiple Myeloma:

Of the approximately 1,200 Australians who are diagnosed with multiple myeloma each year, almost all are older than 40 years. Multiple myeloma is most common in people aged 60 years and older, and men are affected more often than women. In the United States, an estimated 20,520 adults will be diagnosed with multiple myeloma. It is estimated that 10,610 deaths from this disease will occur this year. The five-year survival rate (percentage of people who survive at least five years after the cancer is detected, excluding those who die from other diseases) of people with multiple myeloma is about 39%. However, several factors affect an individual's survival, such as the person's age and overall health.